Anne Kerber, Emma Lees and Monica Shaw share how we are driving innovation in lung cancer care with the goal of improving outcomes for patients. While new cases and deaths have declined, lung cancer remains aggressive and more work is needed. This #LungCancerAwarenessMonth, learn more about our commitment to transforming the treatment paradigm. https://bit.ly/448ujLL #DecodedByBMS #OneBMS
Incredible commitment by Bristol Myers Squibb — bridging discovery and access to reframe lung cancer care with science that doesn’t stop at the lab 👏
L' humain associé au savoir dans son implication à toujours vouloir exceller ne peut que contribuer à la réussite. Au plaisir d'échanger sur vos besoins éventuels en qualité. Félicitations Bristol Myers Squibb 👍
Important insights from Anne Kerber, Emma Lees and Monica Shaw. It’s encouraging to see BMS continuing to push innovation in lung cancer care, especially in such a complex and aggressive disease area. Grateful for the dedication to improving outcomes for patients.
BMS’ approach to lung-cancer care is inspiring. As a recent engineering graduate in formulation, I’m particularly interested in how delivery science and formulation strategies support these innovations, to overcome resistance mechanisms and to ensure accessibility across different profiles. I'm also curious to learn how formulation and translational science teams collaborate in this journey.
Patient Market Intelligence for Pharma | Mapping 13,000+ Global Advocacy Groups in Real Time
2dThis made me pause in a good way. It’s a reminder of how much uncertainty and emotional weight patients and families carry when facing something as unforgiving as lung cancer. And it shows how much impact thoughtful alignment across science, access, and real-world care can have when the system moves with intention. Really meaningful to see.